Paying for expensive new technologies: Medicare's experiences with recombinant erythropoietin.
Coster
J M
JM
U.S. Senate, Special Committee on Aging, Washington, D.C. 20510.
Gianfrancesco
F
F
Chuldzinski
P
P
D001709:Biotechnology / Q000191:economics; D003365:Costs and Cost Analysis; D004921:Erythropoietin / Q000627:therapeutic use*; D006410:Hematopoiesis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D006278:Medicare; D011994:Recombinant Proteins; D006435:Renal Dialysis; D014481:United States
D011994:Recombinant Proteins; D004921:Erythropoietin